The effect of intra-articular injection of autologous bone marrow stem cells on pain and knee function in patients with osteoarthritis by Garay Mendoza, Domingo et al.
ORIGINAL ARTICLE
The effect of intra-articular injection of autologous bone
marrow stem cells on pain and knee function in patients
with osteoarthritis
Domingo GARAY-MENDOZA,1 Laura VILLARREAL-MARTINEZ,2
Alejandra GARZA-BEDOLLA,2 Daniela M. PEREZ-GARZA,2 Carlos ACOSTA-OLIVO,1
Felix VILCHEZ-CAVAZOS,1 Cesar DIAZ-HUTCHINSON,1 David G OMEZ-ALMAGUER,2
Jose C. JAIME-PEREZ2 and Consuelo MANCIAS-GUERRA2
1Traumatology and Orthopaedics Service, Hospital Universitario “Dr. Jose Eleuterio Gonzalez”, Universidad Autonoma de Nuevo
Leon, and 2Hematology Service, Hospital Universitario “Dr. Jose Eleuterio Gonzalez”, Universidad Autonoma de Nuevo Leon,
Monterrey, Mexico
Abstract
Aim: Management of osteoarthritis (OA) is basically symptomatic. Recently, stem cells (SC) have been used in
the search for an optimum treatment. We decided to conduct a controlled clinical trial to determine if a single
intra-articular injection of in vivo stimulated bone marrow SC could lead to an improvement in pain manage-
ment and quality of life in patients with knee OA.
Method: This was a prospective, open-label, phase I/II clinical trial to assess the safety and efficacy of a sin-
gle intra-articular injection of autologous stimulated bone marrow stem cells (BM-SC) in patients with knee
OA. Individuals of both genders older than 30 years with confirmed diagnosis of OA who signed informed
consent were included in two groups: SC group received in vivo BM stimulation with subcutaneous admin-
istration of granulocyte colony stimulating factor (G-CSF). SC were obtained by BM aspiration and admin-
istered in a single intra-articular injection. The control group received exclusively oral acetaminophen.
Visual analogue scale and Western Ontario and McMaster Universities Osteoarthritis Index scores were per-
formed at 1 week, 1 month and 6 months in both groups. This trial was registered in ClinialTrials.gov
NCT01485198.
Results: A total of 61 patients were included. Socio-demographic characteristics, OA grades and initial scores
were similar in both groups. The BM-SC group showed significant improvement in knee pain and quality of life
during the 6-month follow-up.
Conclusion: The study demonstrates feasibility and supports efficacy of a completely ambulatory procedure in
treatment of knee OA.
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INTRODUCTION
Osteoarthritis (OA) is the most common musculoskele-
tal disease and occurs in around 15% of the world pop-
ulation over 60 years of age. It is a painful and
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disabling degenerative disease that can affect any joint,
with the knee being the most common site.1 The risk of
developing OA increases with each decade after
45 years of age.2 In OA numerous biological molecules
produce cartilage destruction. Chondrocytes produce
mediators of inflammation such as cytokines, chemoki-
nes, and proteolytic enzymes that induce further dam-
age. The progression of OA can lead to total knee
replacement, which carries important costs and possible
serious complications.
Currently OA treatment is mostly pharmacologic and
symptomatic, with optimum treatment requiring effec-
tive analgesia, improving joint function, stopping pro-
gression of chondral degeneration, and if possible,
regenerating damaged cartilage. There is no treatment
available to stop progression or revert damage already
present. Acetaminophen is the drug of choice for pain
management due to its safety at recommended doses.1,3
It has been used for pain relief in OA for about a cen-
tury; however, its efficacy has been recently challenged
in a systematic review.4 Thus, an effective, safe and low-
cost treatment for OA is necessary. Ideal therapy should
provide pain relief, stop progression, modify cartilage
structure and revert damage.5 New treatment options
include tissue engineering for tissue regeneration,
which includes harvesting and transplant methods.6,7
Tissue auto-transplant is a well-established strategy for
treatment of damaged or lost tissue after a trauma,
oncological resection, congenital deformities or pro-
gressing degenerative disease.8
In this field stem cells (SC) have been studied. There
are different sources of adult SC; the most common is
bone marrow (BM), where they are harvested and
administrated locally or systemically. In cell therapy,
BM offers some advantages over other sites of collection
because it offers a higher concentration of SC in less
volume, it is of easy access, there is no need for a central
venous catheter, and excludes performing more trouble-
some procedures like apheresis.9 These cells have the
potential of producing therapeutic effects based on their
capacity to regenerate joint chondral lesions and relieve
symptoms, particularly those due to the secretion of
diverse factors and cell-to-cell interaction.10 Also, there
are additional advantages in centers with budget and
bed availability limitations, as the procedure can be a
totally outpatient intervention and only a visit to the
hospital is needed for collecting, processing and inject-
ing SC.
There are few studies reporting outcomes after stem
cell therapy in knee OA.11 Centeno et al. and Wakitani
et al.12,13 reported the first OA cases treated with BM-SC
injection with promising results. Importantly, there are
no previous reports of in vivo BM stimulation followed
by a single SC intra-articular injection without surgical
intervention. We conducted a prospective trial to deter-
mine if intra-articular injection of in vivo stimulated
BM-SC is a safe procedure and could lead to improve-
ment in pain management and quality of life in
patients with knee OA.
PATIENTS AND METHODS
Study design
This was a prospective, open-label, phase I/II clinical
trial to assess the safety, tolerability and efficacy of a sin-
gle intra-articular injection of autologous bone marrow
stem cells (BM-SC) in patients with knee OA.
Patients were recruited from the orthopedic surgery
clinic and the intervention procedure was carried out at
the hematology service, both from the University
Hospital “Dr. Jose Eleuterio Gonzalez”, Mexico.
Patients with the following characteristics were
included: individuals of both genders aged over
30 years and with a confirmed diagnosis of knee OA
made by clinical and radiological evaluation, with
unilateral affection, and at least 6 months of progres-
sion. They were classified as OA grades II and III
according to the Kellgren and Lawrence radiological
classification system. All participants provided
informed consent and were divided into two homoge-
nous groups, in which socio-demographic characteris-
tics, OA grades, and initial visual analogue scale
(VAS), which evaluated pain on a numerical scale
from 0 to 10, where 0 signified no pain and 10 signi-
fied the worst pain experienced by the patient, and
the Western Ontario and McMaster Universities Arthri-
tis Index (WOMAC) scores were equal.
Patients with systemic arthritis, a knee infection or
surgery in the last 6 months, an intra-articular injection
in the past 3 months, or neurodegenerative, autoim-
mune, malignant or traumatic lesions (joint fracture,
meniscal or ligament injury) were excluded. Hypothesis
testing of the difference between two population means
was used to determine sample size.
A knee X-ray in two positions, comparative anterior-
posterior (AP) and lateral in standing position, were
obtained from each participant at the beginning of the
study. VAS and WOMAC scales were made at baseline,
1 week, 1 month, and after 6 months of intervention.
The Review Board and Ethics Committee of our institu-
tion approved the study. This trial was registered in
ClinialTrials.gov NCT01485198.
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Stem cell group
Initial evaluation
Before starting SC stimulation, a complete medical eval-
uation was performed, including medical history, phys-
ical examination, complete blood count and
biochemical profile. Infectious diseases such as human
immunodeficiency virus, hepatitis B and C were ruled
out. Subsequently, VAS and WOMAC data were col-
lected.
Stimulation and harvesting of SC
After overall assessment, autologous SC stimulation
was started with the subcutaneous administration of
600 lg per day of granulocyte colony stimulating factor
(G-CSF) (Biofilgran, Landsteiner Scientific, Mexico City,
Mexico) for 3 consecutive days on an outpatient basis,
before the procedure. A complete blood count (CBC)
was performed to determine the increase in cell concen-
tration in peripheral blood on the day of BM harvesting
(white blood cell count: pre-G-CSF 8.22 9 103 lL,
post-G-CSF: 36.60 9 103 lL). Bone marrow aspiration
was performed using local anesthesia with xylocaine at
2% and with the patient under sedation with intra-
venous midazolam at 0.1 mg/kg. Patients were placed
in the prone position, and after aseptic maneuvers, Jam-
shidi needles (Carefusion Corporation, Chicago, IL,
USA) were inserted in both posterior iliac crests to aspi-
rate a BM volume of 75 mL from each iliac crest. The
harvested BM aspirate was collected in three sterile 50-
mL Corning tubes (Corning Incorporated, Corning,
NY, USA) with a previously added anticoagulant solu-
tion composed of a 1 : 100 dilution of 1000 units of
heparin and citrate dextrose.
Stem cell isolation
BM-derived SC isolation was set to obtain a final vol-
ume of 10 mL for intra-articular administration. After
harvesting, BM contained in the Corning tubes was fil-
tered in a laminar flow cabinet using a 180-l blood fil-
ter. A sample of 0.5 mL was taken to perform BM-CBC.
BM was centrifuged at 26009 g for 15 min at 6°C
and returned to the flow cabinet. Plasma was removed
with a 16-gauge needle 2 mm above the buffy coat and
discarded. The buffy coat was obtained manually with
the use of a 10-mL syringe, in approximately 3.3 mL of
volume for each of the BM harvest tubes. This process
was performed while attempting to obtain a rich-cell
buffy coat with as few red blood cells as possible.
A 0.5-mL sample of the collected buffy coat was used
to perform a CBC, bacterial cultures, and flow cytome-
try for CD45+, CD34+ and viability determination. Flow
cytometry enumeration of CD34+, CD45+ cells and via-
bility assessment were made with the single-platform
ISHAGE (International Society of Hematotherapy and
Graft Engineering) technique in a FACSCalibur cytome-
ter with anti-CD34, anti-CD45 antibodies and 7-ami-
noactinomycin D, respectively. Cells were not selected
or separated by apheresis nor cultured for induction or
expansion.
Intra-articular cell administration
Intra-articular stem cell (IA-SC) injection was made on
the same day, 90 min after the bone marrow harvest-
ing. The patient was placed in a supine position with
the affected knee flexed at 70°. After surgical cleaning
and local anesthesia with 3 mL of 1% xylocaine at the
puncture site, a 10 mL concentrate of BM SCs was
injected with an 18 G 9 1" needle infra-patellar imme-
diately lateral to the patellar tendon into the lateral
compartment intra-articular space of the affected knee.
All patients were injected by the same orthopedic sur-
geon. The intra-articular injection was made on an out-
patient basis.
Control group
Patients enrolled in the control group underwent treat-
ment with oral acetaminophen 500 mg every 8 h for
6 months. As in the SC group, patients were evaluated
with VAS and WOMAC scales at baseline, 1 week,
1 month and 6 months. Between these periods of time
no other intervention was made in this group.
Follow-up and further assessment
Follow-up of patients from both groups was carried out
on an outpatient basis. VAS and WOMAC were per-
formed by the same team at baseline, 1 week, 1 month
and 6 months.
Statistical analysis
For comparisons between groups Student’s t-test was
used for quantitative variables and the Mann–Whitney
U-test for non-parametric variables. Absolute frequen-
cies and percentiles were calculated and compared
using either the Chi-squared test or Fisher’ exact test.
Statistical analysis was made with SPSS version 20
(IBM, Armonk, NY, USA).
RESULTS
A total of 61 patients were recruited: 30 in Group 1 (SC
group) and 31 in Group 2 (acetaminophen group). Ten
patients were lost during follow up, four and six, respec-
tively (Fig. 1).
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Socio-demographic characteristics such as gender,
age, weight, height and body mass index (BMI) were
similar in both groups (Table 1).
According to the OA Kellgren–Lawrence classification
there were no statistically significant differences
between the two groups.
The mean number of BM total nucleated cells was
302.02 9 107 (155 9 107–469.23 9 107), and the
mean number of BM mononuclear cells was
67.33 9 107 (31.52 9 107–114.02 9 107). The mean
number of CD34+ cells injected was 20.56 9 106
(5.2 9 106–43.36 9 106).
Scores
Initial scores for VAS and WOMAC were similar in
both groups: VAS for Group 1 (x  SD):
5.27  2.196 and for Group 2 (x  SD): 4.32  2.35
(P = 0.10). WOMAC for Group 1 (x  SD):
62.61  18.55 compared to Group 2 (x  SD)
69.93  17.89 (P = 0.12). Further evaluations at
1 week, 1 month and 6 months showed a statistically
significant improvement in VAS scale, and 1 month
and 6 months in WOMAC for Group 1 (Table 2,
Fig. 2). Data between genders comparing initial scores
with follow up are presented in Table 3. The mean
number of CD34+ cells injected was 20.56 9 106
(range: 5.2 9 106–43.36 9 106).
Adverse events
A patient from Group 1 presented swelling and pain in
the knee the day after the SC-IA injection. Infection was
ruled out and the patient recovered without further
complications. Bone pain was referred by 12 patients
during the stimulation with G-CSF. Some patients
referred slight pain and stiffness during the first 48 h
after the injection. No other clinical complications were
noticed.
Figure 1 Patient distribution.
Table 1 Comparison of demographic characteristics between
groups
Characteristic Group 1 Group 2 P-value
N 30 31 —
Gender
Male 7 (23%) 9 (29%) —
Female 23 (77%) 22 (71%)
Weight, kg 78.23  13.00 80.41  17.52 0.58
Height, m 1.63  0.07 1.59  0.86 0.10
Age, years 55.67  12.02 59.32  10.85 0.21
BMI, kg/m2 29.48  5.22 31.61  7.38 0.20
BMI, body mass index.









VAS 1 week 2.31  2.24 4.40  2.44 0.003
VAS 1 month 1.62  2.04 4.24  2.72 < 0.0001
VAS 6 months 0.92  1.29 4.64  2.43 < 0.0001
WOMAC
1 week
80.72  20.41 71.62  14.62 0.07
Pain 82.59  15.15 71.07  17.12 0.011
Stiffness 85.26  18.95 65.59  22.40 0.001
Physical
function
80.50  19.65 74.52  15.95 0.218
WOMAC
1 month
88.58  17.12 69.92  14.87 < 0.0001
Pain 88.70  17.24 70.35  17.37 < 0.001
Stiffness 88.88  20.31 67.59  23.57 0.001
Physical
function
87.62  17.61 73.34  16.22 0.003
WOMAC
6 months
91.73  9.45 72.96  15.04 < 0.0001
Pain 92.30  9.40 68.80  18.44 < 0.001
Stiffness 92.30  11.22 70.00  21.65 < 0.001
Physical
function
91.48  9.79 72.29  14.84 < 0.001
Scores are based on a 0–100 point scale (100 points indicates the best
score). Each subscale of WOMAC is based on a 0–100 point scale.
VAS, visual analogye scale; WOMAC, Western Ontario and McMaster
Universities Osteoarthritis Index.
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DISCUSSION
As recently reviewed,14 current research focuses on the
development of new OA drugs, including recombinant
human fibroblast growth factor-18, tanezumab mono-
clonal antibody against b-nerve growth factor15 pursu-
ing greater effectiveness and lower rates of adverse
events. Regenerative approaches, including autologous
chondrocyte implantation (ACI), cell-free scaffolds and
induced pluripotent stem cells, among others, are plau-
sible alternatives to enhance cartilage repair, and restore
healthy tissue.14 Despite these advances, much remains
to be done in order to provide effective treatment
options for OA. In our study, the beneficial effect of
BM-SC was evaluated in knee OA. As mentioned before,
we decided to use autologous BM because it has a
higher concentration of SC in less volume, and has an
easier access, also this protocol is financially sustain-
able, is carried out totally in an outpatient setting and
we have experience performing it for hematologic and
non-hematologic diseases.9,16 Systemic mobilization of
SC and other BM precursors (CD34+) using growth fac-
tors represents minimum manipulation and conse-
quently a reduction in the risk of introducing viruses
and prions.17,18 Therefore, we used SC from BM stimu-
lated in vivo. It is important to consider that BM
hematopoietic stem cells, mesenchymal progenitors
and immune cells increase significantly after G-CSF
stimulation in vivo.19 Furthermore, in the present study
G-CSF was used for stimulation in vivo because there is
an age-dependent factor which has influence in the
decrease in the number of progenitor cells in BM in
elderly patients20 and G-CSF increases the number of
hematopoietic stem cells in BM.21,22 The safe use of G-
CSF in healthy donors has been studied, with minor
side effects such as headache, bone pain, weakness and
nausea, which are generally transient and well toler-
ated.23
Regarding the control group we used paracetamol
since it was considered as the first line treatment, reliev-
ing pain and improving physical functioning with low
long-term toxicity.3
To our knowledge this is the first clinical controlled
trial with autologous BM-SC stimulated in vivo with a
single intra-articular injection for the treatment of knee
OA. Our study differs from other research developed in
Figure 2 Graph showing visual analogue (VAS) and Western
Ontario and McMaster Universities Osteoarthritis Index
(WOMAC) scores: Group 1 versus Group 2.
Table 3 Differences between genders comparing initial scores with scores at 7, 30 and 180 days
Group 1 Group 2
Male N = 7 Female N = 23 Male N = 9 Female N = 22
(x  DS) P (x  DS) P (x  DS) P (x  DS) P
WOMAC_0 75.05  15.12 59.38  18.67 75.62  18.26 67.62  17.61
WOMAC_7 82.42  14.88 0.135 80.70  20.88 < 0.001 71.20  13.73 0.728 72.45  15.10 0.082
WOMAC_30 85.42  20.62 0.024 88.65  16.61 < 0.001 72.95  17.70 0.988 69.52  13.81 0.883
WOMAC_180 88.24  11.66 0.007 92.70  8.87 < 0.001 75.38  13.23 0.68 71.81  16.07 0.252
VAS_0 6  1.78 5.08  2.28 4.44  1.94 4.27  2.49
VAS_7 3  1.41 0.018 2.09  1.75 < 0.001 5.25  2.81 0.685 4.15  2.25 0.929
VAS_30 3  4.76 0.182 1.39  1.11 < 0.001 5.00  3.024 0.857 4.00  2.66 0.884
VAS_180 88.24  11.66 0.007 92.70  8.87 < 0.001 75.38  13.23 0.68 71.81  16.07 0.252
WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index; VAS
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recent years regarding the potential of SC in cartilage
regeneration using different techniques and SC sources.
Previous studies in animal models have demonstrated
the potential benefit of stem cells in cartilage degenera-
tion.24–29 In humans, other studies have been per-
formed using stem cells from different collection sites
such as adipose tissue30–33 or peripheral blood through
apheresis.34,35 Some studies include case series and clin-
ical trials with BM mesenchymal cells; some of them
administered the cells by means of surgical interven-
tion13,36–38 and others with intra-articular injec-
tion.12,39–42
We evaluated our results by means of VAS and
WOMAC scales, since these have been used in many
other knee OA studies,40 in order to determine knee
function and pain, and found that there was an
improvement from the first week in the BM-SC group.
In this setting it is possible that SCs have an anti-
inflammatory effect, which could explain the short-term
clinical improvement. The immunoregulatory effects
strongly inhibit T-cell recognition and expansion by
inhibiting tumor necrosis factor-a and interferon-c pro-
duction and thus, increasing interleukin-10 levels.43
This benefit continued with a rising trend during subse-
quent evaluations. The BM-SC group obtained a signifi-
cant improvement in knee pain and quality of life since
first evaluation until the last one at 6 months.
Our study has important limitations, such as a short
follow-up and the absence of a radiological study or his-
tological examination to demonstrate an increase in car-
tilage volume, and also we did not performed a detailed
evaluation of the contralateral knee. However, our main
goal, to assess safety, tolerability and efficacy of autolo-
gous SC intra-articular injection for pain control in knee
OA was successfully accomplished. The advantages of
the methodology employed are easy access to SCs, no
need for hospitalization or in vitro cell expansion, due
to in vivo stimulation which importantly decrease the
disadvantages of manipulation and high cost.
In conclusion, the present study demonstrates the
feasibility of a completely ambulatory procedure with a
low risk and low possibility of complication. This sug-
gests that the use of autologous BM-SC could be a
promising potential therapy for knee OA, and interest-
ing area of future research.
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